Qingdao Haier Biomedical Co., Ltd.'s merger plan for "Blood King" has failed.
A specific plan recognized by all relevant parties could not be formed.
Due to a lack of consensus among all parties, Qingdao Haier Biomedical Co., Ltd. has pressed the termination button on the merger with Shanghai RAAS Blood Products | Read the announcement quickly.
① The reason for terminating the reorganization is that the main shareholders of the trading parties and the merging parties failed to formulate a specific plan recognized by all relevant parties; ② Shanghai RAAS Blood Products and Qingdao Haier Biomedical Co., Ltd. will resume trading on January 7 and announce a share buyback simultaneously; ③ According to informed sources, the goal of Haier Group to expand its health sector will not change.
The final chapter of the litigation battle between the two state-owned enterprises in Nanjing: Soho Holly Corporation's compensation is determined, with profits expected to decrease by over 30 million in 2024.|Quick read announcement.
① The judgment of the second instance (final judgment) of the lawsuit between Soho Holly Corporation and Nanjing Business & Tourism Corp., Ltd. is to reject the appeal and uphold the original ruling, with the former paying the latter 22.122 million yuan in goods payment and penalty; ② Both parties are state-owned enterprises and located relatively close to each other, but the litigation dispute has been prolonged, originating from a contract fraud committed by Soho Holly Corporation employees; ③ Soho Holly Corporation stated that this matter will impact the company's profit and loss for the year 2024, with the estimated amount being approximately 30.17 million yuan.
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
As the Spring Festival holiday approaches, the tourism Industry is expected to pick up, and these Concept stocks are frequently being investigated.
The Spring Festival holiday is from January 28 to February 4, 2025, totaling 8 days.
Jinyu bio-technology: The industry is in the lowest valley period in history. New products next year will contribute to revenue growth | Directly addressing the earnings conference.
①At the performance briefing, jinyu bio-technology's chairman Zhang Chongyu frankly admitted that the industry is currently experiencing the lowest trough in history; ②The company stated that the competition in the pig vaccine sector is intense, and it will maintain its market share. Several new vaccines will be launched in the next two years. It is expected that the new products next year will contribute to a certain increase in revenue.